Search
Showing results for "Professor"
News & Events
WA partnership to unlock new antibiotic weaponThe Kids Research Institute Australia and WA pharmaceuticals company Boulos and Cooper have signed a $685,000 agreement to develop what could be the first new class of antibiotics in decades.
News & Events
National guidelines bring new order to autism diagnosisClinicians across Australia are looking forward to the release of the country’s first national guidelines for the diagnosis of autism.
Research
A pilot study into assessing the danger of heated-tobacco-productsAlexander Anthony Dr Katherine Larcombe Kicic Landwehr BScEnv (Hons) PhD BSc (Hons) PhD BSc(Hons) Honorary Research Fellow Rothwell Family Fellow;
Research
Penicillin Levels for Rheumatic Heart Disease Study - WA Urban CohortJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxisJonathan Rosemary Carapetis AM Wyber AM MBBS FRACP FAFPHM PhD FAHMS MBChB MPH FRACGP PhD Executive Director; Co-Head, Strep A Translation; Co-Founder
Research
Small-area geographical variation in the prevalence of diabetes amongst Australian youth aged <20 years in 2021To characterise small-area geographical variation in the prevalence of diabetes in Australian youth. A combined statistical reconstruction and small-area estimation algorithm was applied to privacy-modulated data from the 2021 Australian Census.
Research
Geospatial joint modeling of vector and parasite serology to microstratify malaria transmissionThe World Health Organization identifies a strong surveillance system for malaria and its mosquito vector as an essential pillar of the malaria elimination agenda. Anopheles salivary antibodies are emerging biomarkers of exposure to mosquito bites that potentially overcome sensitivity and logistical constraints of traditional entomological surveys.
Research
The economic and health burdens of diseases caused by group A Streptococcus in New ZealandIn preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.
Research
Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection studyWe review the Group A Streptococcus Human infection studies and present the study protocol for a dose-ranging inpatient study in healthy adults
Research
Standardizing clinical care measures of rheumatic heart disease in pregnancy: A qualitative synthesisPregnancy provides an opportunity to strengthen health system responses and address whole-of-life health for women with rheumatic heart disease